Cargando…
Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797678/ https://www.ncbi.nlm.nih.gov/pubmed/35117143 http://dx.doi.org/10.21037/tcr.2019.06.21 |
| _version_ | 1784641609404514304 |
|---|---|
| author | Rebuzzi, Sara Elena Facchinetti, Francesco Tiseo, Marcello |
| author_facet | Rebuzzi, Sara Elena Facchinetti, Francesco Tiseo, Marcello |
| author_sort | Rebuzzi, Sara Elena |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8797678 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87976782022-02-02 Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study Rebuzzi, Sara Elena Facchinetti, Francesco Tiseo, Marcello Transl Cancer Res Editorial Commentary AME Publishing Company 2019-12 /pmc/articles/PMC8797678/ /pubmed/35117143 http://dx.doi.org/10.21037/tcr.2019.06.21 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Commentary Rebuzzi, Sara Elena Facchinetti, Francesco Tiseo, Marcello Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study |
| title | Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study |
| title_full | Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study |
| title_fullStr | Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study |
| title_full_unstemmed | Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study |
| title_short | Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study |
| title_sort | anti-angiogenesis boosts chemo-immunotherapy in patients with egfr mutations or baseline liver metastases: insights from impower150 study |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797678/ https://www.ncbi.nlm.nih.gov/pubmed/35117143 http://dx.doi.org/10.21037/tcr.2019.06.21 |
| work_keys_str_mv | AT rebuzzisaraelena antiangiogenesisboostschemoimmunotherapyinpatientswithegfrmutationsorbaselinelivermetastasesinsightsfromimpower150study AT facchinettifrancesco antiangiogenesisboostschemoimmunotherapyinpatientswithegfrmutationsorbaselinelivermetastasesinsightsfromimpower150study AT tiseomarcello antiangiogenesisboostschemoimmunotherapyinpatientswithegfrmutationsorbaselinelivermetastasesinsightsfromimpower150study |